Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch
GeekWire
JULY 7, 2021
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Pacific Northwest biotechs that have gone public this year include Sana Biotechnology, which raised $587 million in its February IPO and Impel NeuroPharma, which raised $80 million through its IPO in April.
141 
Let's personalize your content